| Title： | Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023 edition) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Doctors |
| Evidence classification method： | Table 1. Level of evidence in evidence-based medicine Level of evidence Description Ⅰa The evidence comes from a meta-analysis of multiple randomized controlled studies Ⅰb The evidence comes from at least one well-designed randomized controlled study Ⅱa The evidence comes from at least one well-designed prospective non-randomized controlled study Ⅱb The evidence comes from at least one well-designed interventional clinical study of other types Ⅲ The evidence comes from well-designed non-interventional studies, such as descriptive and correlation studies. Ⅳ The evidence comes from reports of the expert committee or clinical experience reports of authoritative experts Table 2. Levels of expert recommendations Level of evidence Description A Good scientific evidence suggests that the medical treatment confers clear benefits; it is recommended that physicians perform the medical treatment on patients. B Existing evidence shows that the medical treatment can confer moderate benefits that outweigh its potential risks; physicians can recommend or perform the medical treatment on patients. C Existing evidence shows that the medical treatment may have little benefit, or the benefit is close to the risk; physicians can selectively recommend and perform the medical treatment on patients according to their individual condition. D Existing evidence shows that the medical treatment has no benefit, or its potential risks outweigh the benefits; it is not appropriate for physicians to perform the medical treatment on patients. I There is a lack of scientific evidence, or existing evidence cannot be used to evaluate the benefits and risks of the medical treatment; physicians should help the patients understand the uncertainty of the medical treatment. |
| Development unit： | Chinese Association of Liver Cancer and Chinese Medical Doctor Association |
| Registration time: | 2023-05-26 |
| Registration number： | PREPARE-2023CN365 |
| Purpose of the guideline: | To better guide the whole-course management of hepatocellular carcinoma, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association organized domestic experts in relevant fields to develop the "Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023 edition)", in order to provide theoretical and practical references for colleagues engaged in HCC related clinical work. |
Latest registration
